Cowen Inc’s Myriad Genetics MYGN Stock Holding History

Cowen Inc’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-21,400	Closed	-$575K	–	259
2013 Q2	$575K	Buy	+21,400	New	+$620K	0.06%	151

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cowen Inc's MYGN Position: Q3 2015 in Review

Cowen Inc sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 2,000 shares.

Cowen Inc first reported a position in MYGN in Q4 2013 and held it in 2 quarters. The position peaked at $63K in Q4 2013. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

Cowen Inc reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
Cowen Inc sold 2,000 Myriad Genetics shares in Q3 2015.
Cowen Inc first reported a position in Myriad Genetics in Q4 2013 and held it in 2 quarters.
Cowen Inc's Myriad Genetics position peaked at $63K in Q4 2013.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on Cowen Inc's 13F filing for Q3 2015, filed 13 Nov 2015.